The Daily Toke

April 12, 2026

# THC & POLITICS: Federal Rescheduling Stalls While States Push Forward

President Trump signed an executive order in December 2025 directing federal rescheduling of marijuana, signaling a significant pivot in federal cannabis policy after decades of Schedule I classification. Yet four months later, progress has stalled. A Trump administration advisor disclosed in April that "someone is holding up" the rescheduling process, suggesting bureaucratic resistance or competing interests within the federal apparatus are preventing implementation of the president's own directive. The delay underscores a recurring pattern in cannabis policy: executive intent and legislative reality rarely move in sync, leaving the cannabis industry and consumers in a state of prolonged uncertainty about what federal rescheduling actually means in practice.

Pennsylvania Governor Josh Shapiro intensified his state-level legalization push in early April, exemplifying how states are moving ahead regardless of federal delays. While Shapiro advocates for adult-use legalization, the federal government's inability to execute rescheduling within months of a presidential order reveals the structural inertia built into cannabis prohibition—a framework that has remained essentially unchanged since Nixon's 1970 Controlled Substances Act, despite his own Shafer Commission recommending decriminalization over 50 years ago. 🚀 THIS IS COOL The distinction matters: rescheduling isn't legalization. It's recategorization—potentially moving cannabis from Schedule I (no accepted medical use) to a lower schedule, which could unlock research opportunities and reduce criminal penalties while leaving state-level prohibition intact.

The workplace implications are already creating confusion. Legal analysts are grappling with how Trump's executive action translates to employment law, given that rescheduling at the federal level doesn't automatically override state bans, state legalization frameworks, or employer drug-testing policies. 💰 MONEY MOVES This legal ambiguity directly impacts the cannabis industry's ability to scale—investors need clarity before committing capital to multi-state operations, and businesses cannot confidently expand across state lines when federal status remains fluid. The April delays mean that rescheduling, once positioned as imminent, is now indefinite, extending the period where cannabis occupies a legal gray zone that frustrates entrepreneurs, patients, researchers, and workers alike.

The stall in federal rescheduling has real consequences for cannabis research and medical applications. One of the primary benefits of rescheduling is unlocking DEA-restricted research pathways, allowing scientists to study cannabis compounds and their therapeutic potential more freely. Veterans in particular face narrowed options: many rely on legal THC products for PTSD, chronic pain, and anxiety management in states where cannabis is permitted, but federal rescheduling delays mean federally funded VA research into these applications remains bottlenecked. Meanwhile, prescription opioids—which kill over 16,000 Americans annually—remain Schedule II, fully researched, widely prescribed, and legal. 🤔 THINK ABOUT IT The federal government is actively slowing a rescheduling directive for a plant with zero recorded overdose deaths in human history, while maintaining legal structures that enable mass prescribing of drugs that kill tens of thousands every year—all in the name of safety.

State-level momentum continues regardless. Pennsylvania's push, combined with existing legal frameworks in nearly 24 states for recreational use and 38 for medical, means the federal-state cannabis policy divide is deepening. 💰 MONEY MOVES State tax revenues from cannabis have exceeded $5 billion since legalization began, yet federal classification prevents those businesses from accessing banking, deducting business expenses, or operating across state lines legally. The longer federal rescheduling stalls, the more incentive states have to act unilaterally, deepening the contradiction between federal law and the reality on the ground. The Trump administration's apparent inability to move its own directive suggests that cannabis prohibition—despite changing political winds—remains structurally embedded in federal bureaucracy, enforcement agencies, and competing political interests. Until that inertia breaks, rescheduling remains a promise deferred, not a policy delivered.

April 12, 2026

# Cannabis Business Briefing

Cannabis remains one of the most used drugs in the United States, with 35.4% of people aged 18 to 25 reporting use in the past year, according to recent data. The plant itself—scientifically classified as *Cannabis sativa L*—contains over 500 chemical substances, including at least 125 different cannabinoids. The two most studied are tetrahydrocannabinol (THC), the compound responsible for intoxicating effects, and cannabidiol (CBD), which is non-intoxicating and increasingly marketed for therapeutic applications ranging from inflammation and pain relief to anxiety management. The plant originated in Asia and has been used for thousands of years, with evidence of cannabis consumption dating back to ancient Scythian funerals, but its modern recreational and medical markets are only now reaching full maturity as legalization spreads across U.S. states.

🚀 THIS IS COOL The therapeutic landscape for cannabis continues to expand beyond traditional smoking and vaping. Products now include oils, concentrates, edibles, and specialized formulations—with Epidiolex becoming the first FDA-approved prescription medication containing CBD, specifically for treating certain types of epilepsy. Researchers at the National Institute on Drug Abuse continue funding studies on health effects, cannabis use disorder treatment, and the potential therapeutic applications of various cannabinoid compounds, acknowledging that scientists still have significant unknowns about long-term and short-term effects. Several U.S. states have already established frameworks for medical cannabis use, primarily for symptom management in conditions like chronic pain, neuropathic pain, glaucoma, and poor appetite.

The distinction between "cannabis" and "marijuana" has become important in the evolving legal and commercial landscape. Cannabis refers to all products derived from the *Cannabis sativa* plant, while marijuana specifically refers to cannabis products containing substantial amounts of THC. Hemp—cannabis plants with very small, non-intoxicating amounts of THC—is mainly used for textile fiber and edible seed oils. 💰 MONEY MOVES This terminology shift reflects a broader normalization effort as legalization expands; more people now use the term "cannabis" instead of "marijuana," partly because the latter term is falling out of favor due to its documented racist history in drug enforcement policy. The term "cannabis" is increasingly viewed as more neutral and scientifically accurate.

🤔 THINK ABOUT IT Cannabis has zero recorded overdose deaths in human history, yet remains classified as Schedule I under the Controlled Substances Act—a classification that has persisted for over 50 years despite the Shafer Commission recommending decriminalization back in 1970. Meanwhile, alcohol kills approximately 95,000 Americans per year, and prescription opioids cause over 16,000 deaths annually. The contrast raises fundamental questions about how policy risk assessment actually works, and whether classification reflects scientific evidence or historical precedent. Maryland has established a cannabis administration, and stock analysts are now tracking the "10 Biggest Cannabis Stocks in the US and Canada" as institutional investment in the sector grows—a signal that major capital considers legalization inevitable.

As more states implement legalization frameworks, the cannabis industry is transitioning from prohibition-era informality into a regulated commercial sector with established players, acquisition activity, and stock market tracking. The business fundamentals are straightforward: legalization expands market size, creates tax revenue, and allows legitimate companies to operate transparently. Whether cannabis normalization continues at the federal level remains uncertain, but state-level adoption and investor interest suggest the market momentum is already established. The conversation has largely shifted from whether legalization will happen to how quickly, and which companies and states will capture the value created by moving cannabis from illegal markets into regulated ones.

April 12, 2026

Federal crackdown on hemp-derived THC products is accelerating through Congress, with lawmakers responding to pressure from state regulators and the legal marijuana industry to close what they call a regulatory loophole that has allowed intoxicating hemp products to flourish in states where cannabis remains illegal. Multiple bills are being pushed to restrict or ban hemp-derived delta-8, delta-10, and other THC compounds, marking a significant shift in federal hemp policy since the 2018 Farm Bill legalized low-THC hemp cultivation. The movement reflects growing tension between states trying to maintain cannabis prohibition and a booming industry that has exploited the legal gray area around hemp-derived intoxicants.

💰 MONEY MOVES Congressional restrictions on hemp-derived products threaten a $28 billion industry that has grown rapidly over the past five years, with companies scrambling to adjust their business models as lawmakers move toward federal limits on THC content and product types. The proposed crackdown could restore pricing power to state-licensed cannabis markets, which have struggled to compete with cheaper, less-regulated hemp-derived alternatives sold in convenience stores, gas stations, and online retailers. For licensed producers in states with legal cannabis markets, a federal hemp ban represents a potential market correction—but the transition period could be chaotic for the thousands of businesses that have built operations around hemp-derived products.

The federal government is specifically targeting the "hemp THC loophole"—the distinction between marijuana (Schedule I) and hemp (federally legal if under 0.3% THC by dry weight), which has allowed manufacturers to create intoxicating products that are technically legal under federal law but increasingly unwelcome at the state level. States including South Carolina have indicated they may pursue their own restrictions on hemp-derived products in addition to federal action, signaling a coordinated effort to tighten regulations. Veterans and patients who have relied on legal hemp-derived THC products for pain management, PTSD, and anxiety face potential disruption of access to these alternatives, particularly in states where medical cannabis remains prohibited.

🤔 THINK ABOUT IT Federal policy has long treated cannabis and hemp as fundamentally different substances—one Schedule I, one legal—based on THC content thresholds rather than actual intoxication or harm profiles. Yet the same threshold that makes hemp "legal" has enabled a multi-billion-dollar intoxicating products market to operate openly, while states with legal cannabis markets watch their tax revenue and regulated sales compete against unregulated alternatives. If the goal is genuine consumer protection and market fairness, the question becomes whether a hemp ban addresses those concerns or simply protects state-licensed operators from competition—and whether the federal government should spend political capital restricting a product with zero recorded overdose deaths while alcohol kills approximately 95,000 Americans annually and remains legal nationwide.

A Federal Hemp THC Crackdown Could Restore Order and Pricing Power to the legal cannabis market, but it will also eliminate a legal option for consumers in prohibition states and potentially push users toward unregulated or black-market sources. The timeline for federal action remains unclear, though the momentum in Congress suggests restrictions could be finalized within the next legislative session. Companies operating in the hemp space should expect increased scrutiny and may need to pivot toward CBD products or seek licenses in states with legal cannabis markets to survive a potential federal prohibition.

April 12, 2026

Scientific evidence for medical cannabis is sparse, and major clinical reviews are starting to say so publicly. A comprehensive review published in December found little evidence of benefit for most medical conditions, a finding that contradicts years of patient advocacy and anecdotal testimonials that have driven legalization momentum across the United States. The New York Times reported on the research alongside parallel findings from ScienceDaily showing that while some genuine therapeutic applications exist, they're far narrower than the public narrative suggests—and hidden risks deserve serious attention too. Meanwhile, clinical trials at UCHealth and other research institutions are actively working to fill this evidence gap, attempting to separate what actually works from what merely sounds plausible.

🚀 THIS IS COOL The silver lining is that rigorous science is finally happening. Instead of relying on decades-old prohibition-era assumptions or unverified patient reports, researchers are now running proper Phase III clinical trials to identify which conditions THC and CBD actually help with, what dosages matter, and which patient populations benefit most. This is exactly what should have happened in the 1970s—methodical, peer-reviewed investigation of a plant's actual medicinal properties. The gap between hype and evidence is narrowing, slowly, because scientists are actually asking the hard questions.

The evidence shortage for most conditions is real, according to Newswise and institutional reviews: cannabis shows promise for chronic pain, chemotherapy-induced nausea, and multiple sclerosis symptoms, but claims about cancer treatment, autism, ADHD, and numerous other conditions lack the clinical backing that would satisfy regulatory standards. 🤔 THINK ABOUT IT We ban a zero-overdose plant from Schedule I while prescription opioids—which kill over 16,000 Americans annually—remain Schedule II and widely prescribed. Alcohol, legal and unregulated in strength, kills roughly 95,000 Americans every year. The classification system isn't based on harm; it's based on 50-year-old politics that have calcified into law.

💰 MONEY MOVES The reclassification discussions gaining traction under the Trump administration could reshape the entire research and commercial landscape. Moving THC from Schedule I to Schedule III would instantly unlock federal research funding, making large-scale clinical trials feasible for the first time. It would also open doors for seniors, veterans relying on THC for PTSD and chronic pain, and patients in states where intoxicating hemp products offer the only accessible alternative to opioids. The pharmaceutical industry, insurance companies, and state regulators are all watching closely—because reclassification means legitimacy, and legitimacy means market standardization, quality control, and finally, proper dosing guidelines based on actual science rather than street wisdom.

Veterans represent one of the most compelling use cases: many have found THC products effective for PTSD, anxiety, and chronic pain where conventional pharmaceuticals fail or cause severe side effects. Yet federal Schedule I status means VA hospitals still cannot recommend or study cannabis, forcing veterans into a gap where legal state products exist but federal policy pretends they don't. The evidence gap isn't helping them—it's just delaying access while research slowly catches up.

The path forward is clear: finish the clinical trials, publish the results, and let evidence drive policy instead of ideology. Some conditions will show real benefit; others won't. Both outcomes serve patients better than the current limbo, where cannabis remains federally prohibited despite existing in legal markets in 24 states and Washington DC, where millions of people already use it, and where the only real question left is whether science will finally catch up to reality.

April 12, 2026

A federal judge has temporarily blocked Texas's ban on smokeable hemp products, freezing one of the nation's most aggressive state-level cannabis restrictions just weeks after it took effect on March 31. The ruling from the Texas Tribune (April 8, 2026) came after months of escalating regulatory conflict that began when Governor Greg Abbott's administration announced plans to ban all smokeable cannabis products as early as January 25, 2026. The Texas Alcoholic Beverage Commission held a formal hearing in December 2025 to discuss the proposed ban, setting the stage for what became a rapid legislative push that ultimately passed through the Texas Senate Committee in July 2025. The temporary injunction now freezes enforcement while the legal challenge moves forward, casting doubt on whether the ban will ultimately survive judicial review.

The timing of Texas's ban effort is particularly notable given the federal political shift. Just days before the state's December 2025 TABC hearing, President Trump announced plans to ease marijuana regulations at the federal level (Fort Worth Star-Telegram, December 18, 2025), creating a direct contradiction between state prohibition and federal de-escalation. 💰 MONEY MOVES The conflict represents a significant economic battleground: smokeable hemp and delta-8 THC products have become a multi-billion-dollar market in states where federal prohibition still technically applies but state enforcement has remained minimal. Texas's attempted ban targeted that emerging market directly, but the federal signal shift may have weakened the state's legal argument for prohibition.

Governor Abbott had clarified his administration's hemp THC stance while the Senate Committee approved the ban in summer 2025, framing the restriction as a public health matter. Yet the actual harm profile tells a different story. 🤔 THINK ABOUT IT Texas bans a plant product with zero recorded overdose deaths in human history while alcohol—which kills approximately 95,000 Americans annually—remains fully legal and subject to minimal regulatory scrutiny. The state's justification centered on protecting consumers and preventing youth access, but the federal data on teenage substance-related deaths shows alcohol as the #1 drug-related killer of teenagers, not cannabis in any form.

🚀 THIS IS COOL The temporary injunction represents an important moment in how courts are beginning to evaluate cannabis prohibition at the state level. Legal experts suggest that judges are increasingly skeptical of blanket bans on hemp-derived products, particularly when those products exist in a federal gray zone where they're technically Schedule I but not federally prosecuted. Veterans' advocacy groups have also weighed in on the controversy: many Texas veterans use legal THC products for PTSD, chronic pain, and anxiety management, and the ban would have eliminated a therapeutic option with documented clinical support and zero fatal overdose risk.

The legal uncertainty now facing Texas—where a temporary block means smokeable hemp sales can continue while courts decide the broader question—mirrors similar conflicts unfolding in other states. The federal tone shift under Trump's administration, combined with mounting evidence that cannabis bans don't reduce use but do push consumers toward unregulated markets, has given renewed momentum to legal challenges against state-level prohibition. Texas's ban, which seemed certain just weeks ago, now faces an uncertain future in court.